ADVERTISEMENT
Triplet Combo Well-Tolerated, Effective for IDH1-Mutated AML
05/31/2020
Courtney DiNardo, MD, MSCE, The University of Texas MD Anderson Cancer Center, Houston, discusses the promising results from a phase 1b/2 study exploring ivosidenib in combination with venetoclax and azacitidine for IDH1-mutated acute myeloid leukemia (AML). These results were presented at the virtual 2020 ASCO Annual Meeting.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement